

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



B4

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/50, 31/505, 31/42	A1	(11) International Publication Number: WO 00/15230 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/21069 (22) International Filing Date: 13 September 1999 (13.09.99) (30) Priority Data: 60/100,677 17 September 1998 (17.09.98) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [-/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US). (72) Inventors: ROBL, Jeffrey, A.; 7 Tulip Drive, Newtown, PA 18940 (US). PARKER, Rex, A.; 147 Church Road, Titusville, NJ 08560 (US). BILLER, Scott, A.; 31 Second Street, Hopewell, NJ 08525 (US). JAMIL, Haris; 239 Burgundy Lane, Newtown, PA 18940 (US). JACOBSON, Bruce, L.; 368 Vetterlein Avenue, Mercerville, NJ 08619 (US). KODUKULA, Krishna; 33 Douglas Drive, Princeton, NJ 08540 (US). (74) Agents: RODNEY, Burton et al.; Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543-4000 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU-ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION

(57) Abstract

A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING
AN aP2 INHIBITOR AND COMBINATION

Field of the Invention

5 The present invention relates to a method for
treating atherosclerosis and related diseases, employing an
aP2 inhibitor alone or in combination with another type
antiatherosclerotic agent.

10 Background of the Invention

Fatty acid binding proteins (FABPs) are small
cytoplasmic proteins which bind to fatty acids such as
oleic acids which are important metabolic fuels and
cellular regulators. Dysregulation of fatty acid
15 metabolism in adipose tissue is a prominent feature of
insulin resistance and the transition from obesity to non-
insulin dependent diabetes mellitus (NIDDM or Type II
diabetes).

aP2, an abundant 14.6 KDa cytosolic protein in
20 adipocytes, and one of a family of homologous intracellular
fatty acid binding proteins (FABPs), is involved in the
regulation of fatty acid trafficking in adipocytes and
mediates fatty acid fluxes in adipose tissue. G.S.
Hotamisligil et al, "Uncoupling of Obesity from Insulin
25 Resistance Through a Targeted Mutation in aP2, the
Adipocyte Fatty Acid Binding Protein", Science, Vol. 274,
Nov. 22, 1996, pp. 1377-1379, report that aP2-deficient
mice placed on a high fat diet for several weeks developed
dietary obesity, but, unlike control-mice on a similar
30 diet, did not develop insulin resistance or diabetes.
Hotamisligil et al conclude that "aP2 is central to the
pathway that links obesity to insulin resistance"
(Abstract, page 1377).

DIALOG ALERT DBDR928 dates January 2, 1997,
35 Pharmaprojects No. 5149 (Knight-Ridder Information)
discloses that a major drug company "is using virtual
screening techniques to identify potential new antidiabetic

compounds." It is reported that "the company is screening using aP2, a protein related to adipocyte fatty acid binding protein."

5 Description of the Invention

In accordance with the present invention, a method is provided for treating atherosclerosis wherein a therapeutically effective amount of a drug which inhibits aP2 (aP2 inhibitor) is administered to a human patient in
10 need of treatment.

In addition, in accordance with the present invention, a method is provided for treating atherosclerosis, wherein a therapeutically effective amount of a combination of an aP2 inhibitor and another type of
15 antiatherosclerotic agent is administered to a human patient in need of treatment.

Furthermore, in accordance with the present invention, a novel antiatherosclerotic combination is provided which is formed of a drug which inhibits aP2 and
20 an antiatherosclerotic agent which functions by a mechanism other than by inhibiting aP2. The aP2 inhibitor will be employed in a weight ratio to the antiatherosclerotic agent (depending upon its mode of operation) within the range from about 0.01:1 to about 100:1, preferably from about
25 0.5:1 to about 10:1.

It will be appreciated that the method of the invention for treating atherosclerosis employing an aP2 inhibitor alone or in combination with an antiatherosclerotic agent encompasses treating, reducing
30 risk of, inhibiting, preventing and/or reducing or causing regression of atherosclerosis.

The method of the invention also encompasses preventing, inhibiting or reducing risk of cardiovascular and cerebrovascular diseases resulting from
35 atherosclerosis, such as cardiac and/or cerebral ischemia, myocardial infarction, angina, peripheral vascular disease and stroke.

The ap2 inhibitors suitable for use in the method of the invention are compounds which bind to the ap2 protein and inhibits its function and/or its ability to bind free fatty acids. The compounds will preferably contain less than 60 carbon atoms, more preferably less than 45 carbon atoms, and will contain less than 20 heteroatoms, more preferably less than 12 heteroatoms. They contain a hydrogen bond donator or acceptor group, preferably acidic in nature, which includes, but is not limited to, CO₂H, tetrazole, SO₃H, PO₃H, P(R)(O)OH (where R is lower alkyl or lower alkoxy), OH, NHSO₂R' or CONHSO₂R' (where R' is lower alkyl), and thiazolidindione, and interacts (directly or through an intervening water molecule), either by ionic or hydrogen bonding interactions, with one, two, or three of the three amino acid residues, designated as Arg 106, Arg 126 and Tyr 128 in human ap2, within the ap2 protein.

The compounds suitable for use herein preferably contain an additional substituent, preferably hydrophobic in nature, which include the following groups: alkyl, cycloalkyl, aryl, heteroaryl, cycloheteroalkyl, benzo-fused aryl and heteroaryl, and their substituted counterparts. Especially preferred are aryl and substituted aryl groups. More especially preferred is phenyl and halo or methyl substituted phenyl.

The hydrophobic substituent binds to (in) and/or interacts with a discrete pocket within the ap2 protein defined roughly by the amino acid residues Phe 16, Tyr 19, Met 20, Val 23, Val 25, Ala 33, Phe 57, Thr 74, Ala 75, Asp 76, Arg 78 in human ap2. The through space distance from the hydrogen bond donor/acceptor group and the additional substituent group is within the distance of about 7 to about 15 Angstroms.

The above compounds may be employed in the form of pharmaceutically acceptable salts thereof and prodrug esters thereof.

The term "antiatherosclerotic agent" as employed herein refers to antihyperlipidemic agents including HMG

CoA reductase inhibitors, microsomal triglyceride transfer protein (MTP) inhibitors, fibric acid derivatives, squalene synthetase inhibitors and other
5 known cholesterol lowering agents, lipoxxygenase inhibitors, ACAT inhibitors, and PPAR α/γ dual agonists as disclosed hereinafter.

Brief Description of Figure

10

The accompanying Figure is a computer generated image of a partial X-ray structure of compound XVIA (described hereinafter) bound to human aP2.

15

Detailed Description of the Invention


Examples of aP2 inhibitors suitable for use herein include compounds which include an oxazole or analogous ring. Thus, U.S. Patent No. 5,218,124 to Failli et al
20 (the disclosure of which is incorporated herein by reference) discloses compounds, which have activity as aP2 inhibitors and thus suitable for use herein, which include substituted benzoylbenzene, bipheny- and 2-oxazole-alkanoic acid derivatives having the following
25 structure:

I $A(\text{CH}_2)_n\text{O}-\text{B}$

wherein

A is a group having the formula


5




wherein

X is -N- or

10



Z is




15

R^1 is hydrogen, lower alkyl or phenyl;

R^2 is hydrogen or lower alkyl; or

R^1 and R^2 taken together form a benzene ring, with the proviso that when X is -N-, Z is other than




20

R^3 is hydrogen or lower alkyl;

n is 1-2;

B is

25




wherein

Y is OR⁵ or N(OH)R⁸;

R⁴ and R⁵ are each, independently, hydrogen or lower alkyl;

5 R⁶ is hydrogen, halo or nitro;

R⁷ is



R⁸ is lower alkyl;


10 m is 0-3;

and the pharmacologically acceptable salts thereof.

The grouping A embraces, inter alia, 5- or 6-membered unsaturated nitrogen, sulfur or oxygen containing mono- or benzofused-heterocycles, optionally substituted
 15 with lower alkyl or phenyl. The foregoing definition embraces the following heterocyclic moieties; furyl, pyrrolyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, benzofuranyl, benzothienyl, benzothiazolyl, indolyl, benzoxazolyl,
 20 quinazolinyl, benzimidazolyl, quinoxalinyl, quinazolinyl and the like.

Preferred are the examples where A is defined as above and B is


25



and R⁷ is

In another embodiment of the present invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 5,403,852
 30 to Barreau et al (which is incorporated herein by reference) which are oxazole derivatives and have the structure

II



in which;

R and R' are identical or different and represent a
5 hydrogen atom or an alkyl radical containing 1 or 2 carbon
atoms,


R₁ and R₂ are identical or different and represent
hydrogen or halogen atoms or alkyloxy radicals in which the
alkyl portion contains 1 to 4 carbon atoms in a straight or
10 branched chain, and

n equals 3 to 6,

as well to their salts, to their isomers where they exist
and to pharmaceutical compositions containing them.


In addition, other compounds which have activity as
15 aP2 inhibitors suitable for use in the method of the
invention are compounds disclosed in U.S. Patent No.
4,001,228 to Mattalia (which is incorporated herein by
reference) which are 2-thiol-4,5-diphenyloxazole S-
derivatives which have the structure

20 III



wherein m is 0, 1 or 2, n is 1 and R represents hydroxy,
alkoxy or amino. Also included within the scope of this
invention are salts of the compounds of formula III above,
25 particularly pharmaceutically acceptable addition salts
thereof.


Preferred are S-(4,5-diphenyloxazol-2-yl)-
mercaptocarboxylic acids of the formula:



wherein m is 0, 1 or 2, and pharmaceutically acceptable lower alkyl esters and salts thereof.

In another embodiment of the present invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 4,051,250 to Dahm et al (the disclosure of which is incorporated herein by reference) which discloses azole derivatives of the structure

IV






wherein R_1 is carboxyl, esterified carboxyl or other functionally modified carboxyl group; R_2 and R_3 each are aryl of up to 10 carbon atoms; A is C_nH_{2n} in which n is an integer from 1 to 10, inclusive; and Z is O or S, and the physiologically acceptable salts thereof.

Preferred are preferred compounds as disclosed in the Dahm et al patent.


In still another embodiment of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 5,380,854 to Romine et al (the disclosure of which is incorporated herein by reference) and are phenyl-heterocyclic oxazole derivatives which have the structure

V

R is CH_2R^2 ; R^1 is Ph or Th; R^2 is CO_2R^3 , and R^3 is H, or C_1 - C_4 lower alkyl;


or pharmaceutically acceptable salt thereof.

10

Preferred are the compounds where R is $\text{CH}_2\text{CO}_2\text{H}$ andor its tautomer and R^1 is Ph.

In yet another embodiment of the method of the invention, compounds which have activity as aP_2 inhibitors suitable for use herein are disclosed in PCT application WO 95/17393 which are diaryloxazole derivatives having the structure

VI



wherein R¹ is carboxy or protected carboxy,



R² is aryl which may have suitable substituent(s),

5 R³ is aryl which may have suitable substituent(s),

A¹ is lower alkylene,

A² is bond or lower alkylene and

-Q- is




10 (in which is cyclo (lower)alkane or cycle(lower)alkene, each of which may have suitable substituent(s)).

Preferred are the preferred compounds of WO 95/17393 as illustrated by the working Examples thereof.

15 Another embodiment of compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 5,362,879 to Meanwell (the disclosure of which is incorporated herein by reference) which are 4,5-diphenyloxazole derivatives having the structures

20 VIIA




wherein

R is H or C₁-C₅ lower alkyl.

X is N or CH,
 Y is H or CO₂R¹, or COR²,
 R¹ is C₁-C₅ lower alkyl, or phenylmethyl, and
 R² is C₁-C₅ alkyl;

5 VIIB



wherein

R is H or C₁-C₅ lower alkyl,

X is (CH₂)_n or para or meta substituted phenyl

10 wherein the substituent is OR²,

R² is C₁-C₅ alkyl, and

n is an integer of 4 to 8,

and pharmaceutically acceptable salts thereof.


Preferred are the preferred compounds of the

15 Meanwell patent as illustrated by the working Examples thereof.

In still another embodiment of the present invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No.

20 5,187,188 to Meanwell (the disclosure of which is incorporated herein by reference) which are oxazole carboxylic acid derivatives having the structure

VIII



25 wherein

Y and Z are independently hydrogen or together form a bond;

X is CN, CO₂R¹ or CONR²R³;

R and R¹ are independently or together H, Na, or C₁-C₅ lower alkyl;


R² and R³ are independently or together H, or C₁-C₅, lower alkyl;

5 or alkali metal salt thereof.


Preferred are the preferred compounds of the above Meanwell patent as illustrated by the working Examples thereof.

10 In another embodiment of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 5,348,969 to Romine et al (the disclosure of which is incorporated herein by reference) which are phenyloxazolyloxazole derivatives having the structure


15 IX



wherein



20 Y is CH₃, Ph, or OH, provided that when Y is OH, the compound exists in the keto-enol tautomerism form



R¹ is Ph or Th;

R² is CH₂R³;

R³ is CO₂R⁴;


25 R⁴ is H or C₁-C₅ lower alkyl;

R⁵ is H or CH₃; R⁶ is OHCHN or H₂N; and

R⁷ is H or OH;

or pharmaceutically acceptable salt thereof.


Preferred are the preferred compounds as delineated in the Romine et al patent and in the working Examples thereof, especially where X is




5 and R^2 is $\text{CH}_2\text{CO}_2\text{H}$.

In addition, compounds which have activity as aP2 inhibitors which may be employed herein include those disclosed in U.S. Patent No. 5,262,540 to Meanwell (the disclosure of which is incorporated herein by reference) and are 2-(4,5-diaryl)-2-oxazolyl substituted phenoxyalkanoic acids and esters having the structure

XA




XB



15


(wherein n is 7-9 and R is hydrogen or lower alkyl; or when R is hydrogen, the alkali metal salt thereof),

XC



20

XD



wherein

R_1 is phenyl or thienyl;

25 R_2 is hydrogen, lower alkyl or together with CO_2 is tetrazol-1-yl;

X is a divalent connecting group selected from the group consisting of CH_2CH_2 , $\text{CH}=\text{CH}$, and CH_2O ;


Y is a divalent connecting group attached to the 3- or 4-phenyl position selected from the group consisting of OCH_2 , CH_2CH_2 and $\text{CH}=\text{CH}$,

or when R_2 is hydrogen, an alkali metal salt thereof.

Preferred are the preferred compounds as set out in the above Meanwell et al patent as illustrated in the working Examples thereof.

In another embodiment of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in PCT application WO 92/04334 which are substituted 4,5-diaryl heterocycles having the formula

XI



in which

each group Ar is the same or different and is optionally substituted phenyl or optionally substituted heteroaryl;

X is nitrogen or CR^1 ;

Y is nitrogen, $\text{N}(\text{CH}_2)_n\text{A}$ or $\text{C}(\text{CH}_2)_n\text{A}$;

Z is nitrogen, oxygen or $\text{N}(\text{CH}_2)_n\text{A}$, and the dotted line indicates the optional presence of a double bond so as to form a fully unsaturated heterocyclic ring;

R^1 is hydrogen, C_{1-4} alkyl, optionally substituted phenyl or optionally substituted heteroaryl;

n is 4 to 12; and


A is CO_2H or a group hydrolysable to CO_2H , 5-tetrazolyl, SO_3H , $\text{P}(\text{O})(\text{OR})_2$, $\text{P}(\text{O})(\text{OH})_2$, or $\text{P}(\text{O})(\text{R})(\text{OR})$ in which R is hydrogen or C_{1-4} alkyl, or a pharmaceutically acceptable salt thereof.

Preferred are preferred compounds of WO 92/04334.

In yet another embodiment of the invention, compounds which have activity as aP2 inhibitors suitable

for use herein are disclosed in French Patent 2156486 which have the structure

XII



5 Where X is O or S;

R₁ is H, phenyl or phenyl substituted with F, Cl or Br or alkoxy,


R₂ is H, alkyl, phenyl or phenyl substituted with F, Cl or Br or alkoxy, and

10 R₃ is H or alkyl.

Preferred are those preferred compounds as set out in French Patent No. 2156486.

Most preferred oxazole compounds as aP2 inhibitors are the compounds


15



which may be prepared as disclosed in U.S. Patent No. 5,348,969 to Romine et al.

Another class of aP2 inhibitors suitable for use in
 20 the method of the invention include pyrimidine derivatives. Thus, U.S. Patent No. 5,599,770 to Kubota et al (the disclosure of which is incorporated herein by reference) disclose compounds which have activity as aP2 inhibitors and thus suitable for use herein include 2-
 25 benzyloxypyrimidine derivatives having the following structure

XIII



wherein

R^1 and R^2 are each independently H, a halogen, hydroxyl, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_3 - C_5 alkenyl, C_3 - C_5 alkynyl, C_1 - C_4 alkoxy, C_1 - C_4 haloalkoxy, C_3 - C_5 alkenyloxy, C_3 - C_5 alkynyloxy, C_1 - C_4 alkylthio, or phenyl, with the proviso that at least one of R^1 and R^2 must be hydroxyl;


n is an integer of 0 to 5; and

each X which may be identical or different if n is greater than 1, is a halogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_7 - C_9 aralkyloxy, phenyl, hydroxymethyl, hydroxycarbonyl, C_1 - C_4 alkoxycarbonyl, or nitro.

Preferred are the compounds in which either R^1 or R^2 is hydroxyl and the other R^1 or R^2 is C_1 - C_4 alkyl and X is halogen.


In another embodiment of the method of the invention, compounds which have activity as $aP2$ inhibitors suitable for use herein are disclosed in A. Mai et al "Dihydro(alkylthio)-(naphthylmethyl)oxypyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series". J. Med. Chem., 1997, 40, 1447-1454 which have the structures

XIVA



3a R=sec-butyl
3b R=cyclopentyl
3c R=cyclohexyl


XIVB




5 X=CH₂
6 X=O
7 X=S

5


XIVC



XIVD



XIVE




R¹ = sec-butyl, cyclopentyl, cyclohexyl;

R² = H, CH₃. The structures XIVA-XIVE are depicted in


5 their keto form. However, it will be apparent to one skilled in the art that they may also exist in their enol form to give structures of the type

XIVF




10 In yet another embodiment of the method of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in PCT application WO 96/35678 which are α -substituted pyrimidine-thioalkyl and alkylether compounds which have the structure

15 XVI



where m is 0 or 1;

R¹ is selected from -CO₂R₅₃, -CONR₅₄R₅₅,



- where s is 0 or 1, and R_{20} , R_{21} , R_{22} , R_{23} , R_{24} , and R_{25} are the same or different and are selected from -H, C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, C_3 - C_8 cycloalkyl, $-CF_3$, $-NO_2$, -halo, -OH, -CN, phenyl, phenylthio, -styryl, $-CO_2(R_{31})$, $-CON(R_{31})(R_{32})$, $-CO(R_{31})$, $-(CH_2)_n-N(R_{31})(R_{32})$, $-C(OH)(R_{31})(R_{33})$, $-(CH_2)_nN(R_{31})(CO(R_{33}))$, $(CH_2)_nN(R_{31})(SO_2(R_{33}))$, or where R_{20} and R_{21} , or R_{21} and R_{22} , or R_{22} and R_{23} are taken together to form a five or six-membered saturated or unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, -OH, $-CH_2OH$, $-(CH_2)_n-N(R_{31})(R_{32})$, $-C_3$ - C_8 cycloalkyl, $-CF_3$, -halo, $CO_2(R_{31})$, $-CON(R_{31})(R_{32})$, $-CO(R_{31})$, $-(CH_2)_nN(R_{31})(CO(R_{33}))$, $-(CH_2)_nN(R_{31})(SO_2(R_{33}))$, -CN, $-CH_2CF_3$ or $-CH(CF_3)_2$, or phenyl and the saturated ring may be optionally substituted with 1, 2 or 3, $-C_1$ - C_6 alkyl, $-C_1$ - C_6 alkoxy, -OH, $-CH_2OH$ or $-(CH_2)_n-N(R_{31})(R_{32})$ or one oxo ($=O$); where n is 0-3 and R_{31} , R_{32} and R_{33} are the same or different and are selected from
- H,
 - C_1 - C_6 alkyl,
 - phenyl optionally substituted with 1, 2 or 3 -halo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-CF_3$, -OH or -CN,
 - or where R_{31} and R_{32} taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, -4-(1- C_1 - C_6 alkyl)piperazinyl, or a member selected from:
 - 1-cyclohexenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-imidazolyl, 4-imidazolyl, 2-benzothiazolyl, 2-benzoxazolyl, 2-benzimidazolyl, 2-oxazolyl, 4-oxazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 5-methyl-3-

isoxazolyl, 5-phenyl-3-isoxazolyl, 4-thiazolyl, 3-methyl-2-pyrazinyl, 5-methyl-2-pyrazinyl, 6-methyl-2-pyrazinyl, 5-chloro-2-thienyl, 3-furyl, benzofuran-2-yl, benzothien-2-yl, 2H-1-benzopyran-3-yl, 2,3-dihydrobenzopyran-5-yl, 1-methylimidazol-2-yl, quinoxalin-2-yl, piperon-5-yl, 4,7-dichlorobenzoxazol-2-yl, 4,6-dimethylpyrimidin-2-yl, 4-methylpyrimidin-2-yl, 2,4-dimethylpyrimidin-6-yl, 2-methylpyrimidin-4-yl, 4-methylpyrimidin-6-yl, 6-chloropiperon-5-yl, 5-chloroimidazol[1,2-a]pyridin-2-yl, 1-H-inden-3-yl, 1-H-2-methyl-inden-2-yl, 3,4-dihydronaphth-1-yl, S-4-isopropenylcyclohexen-1-yl or 4-dihydronaphth-2-yl;

where R_{53} is selected from -H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, phenyl (optionally substituted with 1, 2, or 3 -halo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-CF_3$, $-OH$, $-CN$), or a five or six-membered unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with -H, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-OH$, $-CH_2OH$, or $-(CH_2)_n-N(R_{31})(R_{32})$;

where R_{54} and R_{55} being the same or different are selected from -H, C_1 - C_6 alkyl, allyl, or phenyl (optionally substituted with 1, 2 or 3 -halo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy or $-CF_3$), or taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, -4-(1- C_1 - C_6 alkyl)piperazinyl;

R_{41} and R_{42} , being the same or different, are selected from -H and C_1 - C_4 alkyl;

R_{12} is selected from -H, C_1 - C_6 alkyl, $-C_3$ - C_6 cycloalkyl, $-CN$, $-C(O)NH_2$, $-C(O)N(C_1-C_6\text{alkyl})(C_1-C_6\text{alkyl})$, $-CO_2H$, $-CO_2(C_1-C_6\text{alkyl})$, $-CH_2OH$, $-CH_2NH_2$ or $-CF_3$;

R_{13} is selected from -H, C_1 - C_6 alkyl or $-CF_3$;

Y is selected from -S-, $-S(O)-$, $-S(O)_2$, or $-O-$;

R_4 is $-OH$;

R_5 is selected from -H, $-C_2H_4OH$, $-C_2H_4O-TBDMS$, halo, $-C_3$ - C_6 cycloalkyl, C_1 - C_3 alkoxy, $-CH_2CH_2Cl$ or C_1 - C_4 alkyl, with the proviso that R_5 is not isobutyl;

or, when R₆ is hydroxyl, R₄ and R₅ are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d]pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidine, furo[2,3-d]pyrimidine, 5,6-dihydro-furo[2,3-d]pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro-thieno[2,3-d]pyrimidine, 1H-pyrazolo[3,4-d]pyrimidine, 1H-purine, pyrimido[4,5-d]pyrimidine, pteridine, pyrido[2,3-d]pyrimidine, or quinazoline, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C₁-C₆ alkyl C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂), -C₃-C₈ cycloalkyl, -CF₃, -halo, -CO₂(R₃₁), -CON(R₃₁)(R₃₂), -CO(R₃₁), -(CH₂)_nN(R₃₁)(CO(R₃₃)), -(CH₂)_nN(R₃₁)(SO₂(R₃₃)), and the saturated ring may be optionally substituted with 1, 2 or 3, -C₁-C₆ alkyl, C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂) or one oxo (=O); and

R₆ is selected from -H, -OH, halo, -CN, -CF₃, -CO₂(R₆₁), -C(O)R₆₁ or -C(O)N(R₆₁)(R₆₂) where R₆₁ and R₆₂ are the same or different and are selected from

-H,

C₁-C₆ alkyl,

phenyl optionally substituted with 1, 2 or 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH, -CN,

or where R₆₁ and R₆₂ taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, or -4-(C₁-C₆ alkyl)piperazinyl; or

pharmaceutically acceptable salts, hydrates, N-oxides and solvates thereof.

A preferred embodiment is pyrimidine-thioalkyl and alkylether, where


R₄ is -OH; and

R₆ is selected from -H, halo, -CN, -CF₃, -CO₂(R₁₆), -C(O)R₆₁ or -C(O)N(R₆₁)(R₆₂), preferably CF₃.

A preferred embodiment are compounds of Formula XVI where s is 0 or 1, and Y is -S- or O; more preferably Y is -S-.


Preferred are pyrimidine derivatives of the
5 structures

XVIA



and


XVIB




10

which may be prepared as disclosed in WO 96/35678.

Another embodiment of the method of the invention includes use of aP2 inhibitors which are pyridazinone derivatives. French Patent No. 2,647,676 discloses
15 compounds which have activity as aP2 inhibitors and thus suitable for use herein which have the structures



XVIIA



XVIIIB

where R₁ and R₂ are H, alkyl, aryl or arylalkyl, where the alkyl can include as substituents halogen, CF₃, CH₃O, CH₃S, NO₂, or R₁ and R₂ with the carbons to which they are
20 attached can form methylenedioxy, or

R₁ and R₂ can form a C₃-C₇ non-aromatic ring, or a heterocycle which can be pyridine, pyrazine, pyrimidine,


pyridazine, indol, or pyrazole, or an oxygen containing heterocycle which can be pyran or furan, or a sulfur containing heterocycle which can be thiopyran, or thiophene; the heterocycles being optionally substituted
 5 with halogen or alkyl,

R_3 and R_4 are H, alkyl, halogen, CF_3 , CH_3O , CH_3S or NO_2 or R_3 and R_4 with the carbons to which they are attached can form a methylenedioxy group,

R_5 is H, and

10 Z is a heterocycle which can be pyridine, thiazole, benzothiazole, benzimidazole or quinoline, which Z group can optionally be substituted with halogen or alkyl.

The preferred pyridazinone derivative is



15


which may be prepared as disclosed in French Patent No. 2,647,676.

Preferred aP2 inhibitors for use herein will include an oxazole ring.

20 Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 40 carbons, preferably 1 to 20 carbons, more preferably 1 to 12 carbons, in the normal
 25 chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1 to

4 substituents such as halo, for example F, Br, Cl or I or CF₃, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, acyl, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl and/or alkylthio.

Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 4 to 12 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,




any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and/or alkylthio.


Unless otherwise indicated the term "aryl" or "Ar" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl) and may optionally include one to three additional rings fused to Ar (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings) and may be optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl,

alkoxy, haloalkoxy, alkenyl, trifluoromethyl,
 trifluoromethoxy, alkynyl, cycloalkylalkyl,
 cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl,
 arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylthio,
 5 arylazo, heteroarylalkyl, heteroarylalkenyl,
 heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano,
 amino, substituted amino wherein the amino includes 1 or 2
 substituents (which are alkyl, aryl or any of the other
 aryl compounds mentioned in the definitions), thiol,
 10 alkylthio, arylthio, heteroarylthio, arylthioalkyl,
 alkoxyarylthio, alkylcarbonyl, arylcarbonyl,
 alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl,
 aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
 alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,
 15 arylsulfinylalkyl, arylsulfonylamino or
 arylsulfonaminocarbonyl.

Unless otherwise indicated the term "aralkyl",
 "aryl-alkyl" or "aryllower alkyl" as used herein alone or
 as part of another group refers to alkyl groups as
 20 discussed above having an aryl substituent, such as benzyl
 or phenethyl, or naphthylpropyl, or an aryl as defined
 above.


Unless otherwise indicated, the term
 "cycloheteroalkyl" as used herein alone or as part of
 25 another group refers to a 5-, 6- or 7-membered saturated or
 partially unsaturated ring which includes 1 to 2 hetero
 atoms such as nitrogen, oxygen and/or sulfur, linked
 through a carbon atom or a heteroatom, where possible,
 optionally via the linker $(CH_2)_p$ (where p is 1, 2 or 3),
 30 such as





and the like. The above groups may include 1 to 3 substituents such as any of the substituents for alkyl or aryl as defined above. In addition, any of the above rings can be fused to 1 or 2 cycloalkyl, aryl, heteroaryl or cycloheteroalkyl rings.

Unless otherwise indicated, the term "heteroaryl" (also referred to as heteroaryl) as used herein alone or as part of another group refers to a 5- or 6-membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), linked through a carbon atom or a heteroatom, where possible, optionally via the linker $(CH_2)_p$ (which is defined above), such as



and the like.


The heteroaryl groups including the above groups may optionally include 1 to 4 substituents such as any of the substituents listed for aryl. In addition, any of the above rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

The term "prodrug esters" as employed herein includes prodrug esters which are known in the art for both

phosphorus and carboxylic acids such as similar carboxylic acid esters such as methyl, ethyl benzyl and the like.


Other examples include the following groups: (1-alkanoyloxy)alkyl such as,

5




wherein R^a , R^b and R^c are H, alkyl, aryl or aryl-alkyl; however R^aO cannot be HO. Examples of such prodrug esters include



10




t-C₄H₉CO₂CH₂-, or



15 Other examples of suitable prodrug esters include



20 wherein R^a can be H, alkyl (such as methyl or t-butyl), arylalkyl (such as benzyl) or aryl (such as phenyl); R^d is H, alkyl, halogen or alkoxy, R^e is alkyl, aryl, arylalkyl or alkoxy, and n_1 is 0, 1 or 2; or



(d is 0 to 3)

Where the aP2 inhibitor is in acid form it may form a pharmaceutically acceptable salt such as alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium as well as zinc or aluminum and other cations such as ammonium, choline, diethanolamine, ethylenediamine, t-butylamine, t-octylamine, dehydroabietylamine.

Where desired, the aP2 inhibitor may be used in combination with another antiatherosclerotic agent which may be administered orally in the same dosage form in accordance with the invention, a separate oral dosage form or by injection.

It is believed that the use of the aP2 inhibitor in combination with another antiatherosclerotic agent produces antiatherosclerotic results greater than that possible from each of these medicaments alone and greater than the combined additive antiatherosclerotic effects produced by these medicaments.


The other antiatherosclerotic agent employed in the methods of the invention include MTP inhibitors disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Application Serial No. 09/175,180 filed October 20, 1998, now U.S. Patent No. _____. Preferred are each of the preferred MTP inhibitors disclosed in each of the above patents and applications.

All of the above U.S. Patents and applications are incorporated herein by reference.

Most preferred MTP inhibitors to be employed in accordance with the present invention include preferred MTP inhibitors as set out in U.S. Patent Nos. 5,739,135 and 5,712,279, and U.S. Patent No. 5,760,246.

Thus, preferred compounds in U.S. Patent Nos. 5,739,135 and 5,712,279 for use herein are compounds of the structure

10




where Z is a bond;


X¹ and X² are H;

15 R⁵ is aryl such as phenyl substituted with



(1) aryl such as phenyl,



(2) heteroaryl such as




(3) halo such as Cl


R⁵ is heteroaryl such as  or  substituted with


20

(1) aroyl such as




(2) arylthio such as



wherein the R⁵ substituent is preferably in the position adjacent to the carbon linked to .


25

(CH₂)_x is -(CH₂)₄- or



Most preferred is


9-[4-{4-[[2-(2,2,2-Trifluoroethoxy)benzoyl]amino]-1-piperidinyl}butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide



5


Preferred compounds in U.S. Patent No. 5,760,246 for use herein are MTP inhibitor compounds which have the formula

10



wherein A is NH,

B is



15

X is a bond, oxygen or sulfur; R³ and R⁴ are independently H or F.

Preferred R¹ groups are aryl, preferably phenyl, heteroaryl, preferably imidazolyl or pyridyl (preferably substituted with one of the preferred R¹ substituents: arylcarbonylamino, heteroarylcarbonylamino, cycloalkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, arylsulfonylamino, heteroaryl-sulfonylamino), PO(OAlkyl)₂, heteroarylthio, benzthi-

20


azole-2-thio, imidazole-2-thio, alkyl, or alkenyl, cycloalkyl such as cyclohexyl, or 1,3-dioxan-2-yl.

Preferred R^2 groups are alkyl, polyfluoroalkyl (such as 1,1,1-trifluoroethyl), alkenyl, aryl or
5 heteroaryl (preferably substituted with one of the preferred R^1 substituents above), or $PO(Oalkyl)_2$.

If R^2 is alkyl, 1,1,1-trifluoroethyl, or alkenyl, it is preferred that R^1 is other than alkyl or alkenyl.

It is preferred that L^1 contains 1 to 5 atoms in
10 the linear chain and L^2 is a bond or lower alkylene.

Most preferred is



The other antiatherosclerotic agent may be an HMG CoA reductase inhibitor which includes, but is not limited to, mevastatin and related compounds as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and
25 related compounds as disclosed in U.S. Patent No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Patent No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171, with pravastatin, lovastatin or
30 simvastatin being preferred. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Patent No. 5,354,772, cerivastatin disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S.
35 Patent Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, pyrazole analogs of mevalonolactone derivatives as disclosed in U.S. Patent No. 4,613,610,

indene analogs of mevalonolactone derivatives as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl]pyran-2-ones and derivatives thereof as disclosed in U.S. Patent No. 5 4,647,576, Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of mevalonolactone as disclosed in PCT application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed in French Patent 10 No. 2,596,393, 2,3-disubstituted pyrrole, furan and thiophene derivatives as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Patent No. 4,686,237, octahydronaphthalenes such as disclosed in 15 U.S. Patent No. 4,499,289, keto analogs of mevinolin (lovastatin) as disclosed in European Patent Application No.0,142,146 A2, as well as other known HMG CoA reductase inhibitors.

In addition, phosphinic acid compounds useful in 20 inhibiting HMG CoA reductase suitable for use herein are disclosed in GB 2205837.

The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α -phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those 25 disclosed by Biller et al, J. Med. Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinylmethyl)phosphonates as well as other squalene synthetase inhibitors as disclosed in U.S. Patent No. 4,871,721 and 4,924,024.

30 In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. 35 Chem. Soc., 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109,

5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary.

- 5 Preferred are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin and cerivastatin.

All of the above U.S. applications are incorporated herein by reference.

- Other cholesterol lowering drugs suitable for use herein include, but are not limited to,
- 10 antihyperlipoproteinemic agents such as fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Patent No. 3,674,836, probucol and
- 15 gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex®, Polidexide®), as well as clofibrate, lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-
- 20 402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted
- 25 urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U.S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and
- 30 ionenes such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents.

The above-mentioned U.S. patents are incorporated herein by reference.

The other antiatherosclerotic agent may also be a PPAR α/γ dual agonist such as disclosed by Murakami et al, "A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferator - Activated Receptor Alpha (PPAR alpha) and PPAR gamma. Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes 47, 1841-1847 (1998).

The other antiatherosclerotic agent may be an ACAT inhibitor such as disclosed in, "The ACAT inhibitor, C1-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al, Atherosclerosis (Shannon, Irel). (1998), 137(1), 77-85; "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein", Ghiselli, Giancarlo, Cardiovasc. Drug Rev. (1998), 16(1), 16-30; "RP 73163: a bioavailable alkylsulfanyl-diphenylimidazole ACAT inhibitor", Smith, C., et al, Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals", Krause et al, Editor(s): Ruffolo, Robert R., Jr.; Hollinger, Manfred A., Inflammation: Mediators Pathways (1995), 173-98, Publisher: CRC, Boca Raton, Fla.; "ACAT inhibitors: potential anti-atherosclerotic agents", Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25; "Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity", Stout et al, Chemtracts: Org. Chem. (1995), 8(6), 359-62.

The other antiatherosclerotic agent may also be a lipoxygenase inhibitor including a 15-lipoxygenase (15-LO) inhibitor such as benzimidazole derivatives as disclosed in WO 97/12615, 15-LO inhibitors as disclosed in WO 97/12613, isothiazolones as disclosed in WO 96/38144, and 15-LO inhibitors as disclosed by Sendobry et al "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties, Brit. J. Pharmacology (1997) 120, 1199-1206, and Cornicelli et al, "15-Lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease", Current Pharmaceutical Design, 1999, 5, 11-20.

The aP2 inhibitor will be employed in a weight ratio to the other antiatherosclerotic agent (where present), in accordance with the present invention, within the range from about 500:1 to about 1:500, preferably from about 100:1 to about 1:100.

The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.

The dosages and formulations for the other antiatherosclerotic agents will be as disclosed in the various patents and applications discussed above.

The dosages and formulations for the other antiatherosclerotic agent to be employed, where applicable, will be as set out in the latest edition of the Physicians' Desk Reference.

For oral administration, a satisfactory result may be obtained employing the MTP inhibitor in an amount within the range of from about 0.01 mg/kg to

about 100 mg/kg and preferably from about 0.1 mg/kg to about 75 mg/kg, one to four times daily.

5 A preferred oral dosage form, such as tablets or capsules, will contain the MTP inhibitor in an amount of from about 1 to about 500 mg, preferably from about 2 to about 400 mg, and more preferably from about 5 to about 250 mg, one to four times daily.

10 For parenteral administration, the MTP inhibitor will be employed in an amount within the range of from about 0.005 mg/kg to about 10 mg/kg and preferably from about 0.005 mg/kg to about 8 mg/kg, one to four times daily.

15 For oral administration, a satisfactory result may be obtained employing an HMG CoA reductase inhibitor, for example, pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin in dosages employed as indicated in the Physician's Desk Reference, such as in an amount within the range of from about 1 to 20 2000 mg, and preferably from about 4 to about 200 mg.

The squalene synthetase inhibitor may be employed in dosages in an amount within the range of from about 10 mg to about 2000 mg and preferably from about 25 mg to about 200 mg.

25 A preferred oral dosage form, such as tablets or capsules, will contain the HMG CoA reductase inhibitor in an amount from about 0.1 to about 100 mg, preferably from about 5 to about 80 mg, and more preferably from about 10 to about 40 mg.

30 A preferred oral dosage form, such as tablets or capsules will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg.

35 The aP2 inhibitor and other antiatherosclerotic agent may be employed together in the same oral dosage form or in separate oral dosage forms taken at the same time.

The compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination.

Tablets of various sizes can be prepared, e.g., of about 2 to 2000 mg in total weight, containing one or both of the active substances in the ranges described above, with the remainder being a physiologically acceptable carrier of other materials according to accepted pharmaceutical practice. These tablets can, of course, be scored to provide for fractional doses. Gelatin capsules can be similarly formulated.

Liquid formulations can also be prepared by dissolving or suspending one or the combination of active substances in a conventional liquid vehicle acceptable for pharmaceutical administration so as to provide the desired dosage in one to four teaspoonsful.

Such dosage forms can be administered to the patient on a regimen of one to four doses per day.

According to another modification, in order to more finely regulate the dosage schedule, the active substances may be administered separately in individual dosage units at the same time or carefully coordinated times. Since blood levels are built up and maintained by a regulated schedule of administration, the same result is achieved by the simultaneous presence of the two substances. The respective substances can be individually formulated in separate unit dosage forms in a manner similar to that described above.

The formulations as described above will be administered for a prolonged period, that is, for as long as the atherosclerotic condition exists. Sustained release forms of such formulations which may provide such amounts biweekly, weekly, monthly and the like, may also be employed.

In carrying out the method of the invention, a pharmaceutical composition will be employed containing at least one aP2 inhibitor with or without an antiatherosclerotic agent in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration. The compounds can be administered to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations. The dose for adults is preferably between 50 and 2,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.

A typical capsule for oral administration contains aP2 inhibitor (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.

A typical injectable preparation is produced by aseptically placing 250 mg of aP2 inhibitor into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

Compounds sufficiently satisfying the structural criteria described above may be determined by use of an in vitro assay system which measures the potentiation of inhibition of aP2 by displacement of a fluorescent substrate from aP2 by the inhibitor. Inhibition constants (K_i values) for the inhibitors may be determined by the method described below:

Production of purified recombinant human aP2 protein. Recombinant human aP2 protein is produced by standard recombinant DNA technology. In the typical case,

- aP2 is produced by heterologous expression in *E. coli* strain BL21(D53) transformed with pET11a vector containing the full length human aP2 cDNA (Baxa, C.A., Sha, R.S., Buel, M.K., Smith, A.J., Matarese, V., Chinander, L.L., Boundy, K.L., and Bernlohr, D.A. (1989). Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. *Biochemistry* 28: 8683-8690 and Xu, Z., Buel, M.K., Banaszak, L.J., and Bernlohr, D.A. (1991). Expression, purification and crystallization of the adipocyte lipid binding protein. *J. Biol. Chem.* 266: 14367-14370). Purification of aP2 from *E. coli* is conducted as described by Xu, yielding essentially homogeneous aP2 protein with molecular weight ~14600 daltons and free of endogenous fatty acids. The purified aP2 is capable of binding up to one mole of free fatty acid per mole protein. The binding and structural properties of recombinant aP2 protein were previously shown to be identical to aP2 protein isolated from adipose tissue.
- 20 **In vitro assay of aP2 inhibitors.** Inhibitors of aP2 are evaluated in a homogeneous fluorescent-based competition assay using recombinant aP2 protein and 1,8-anilino-naphthalene-sulfonic acid (1,8-ANS) as assay substrate. This competition assay was adapted from
- 25 generalized procedures described previously (Kane, C.D. and Bernlohr, D.A. (1996). A simple assay for intracellular lipid-binding proteins using displacement of 1-anilino-8-sulfonic acid. (1996) *Anal. Biochem.* 233: 197-204 and Kurian E., Kirk, W.R. and Prendergast, F.G. (1996) Affinity
- 30 of fatty acid for r-rat intestinal fatty acid binding protein. *Biochemistry*, 35, 3865-3874). The method relies on the increase in fluorescence quantum yield of 1,8-ANS upon binding to the fatty acid binding site of aP2. The assay is run using appropriate concentrations of inhibitor,
- 35 1,8-ANS, and aP2 protein, in order to calculate the inhibitor binding constant (K_i) for compounds being evaluated. The K_i calculation was based on the procedure

previously described for calculation of dissociation constants described by Kurian. Lower K_i values indicate higher affinities of compounds binding to aP2.

In the assay as conducted for the inhibitors described herein, a series of aliquots of aP2 (5 μ M) in solution in 10 mM potassium phosphate buffer (pH 7.0) are mixed with an equimolar concentration of test compound, followed by the addition of a series of increasing concentrations of 1,8-ANS (from 0 to 5 μ M). The assay typically is conducted in 96-well plate format with reagents added using robotic instrumentation (Packard Multiprobe 104). The fluorescence value for each test is determined using a Cytofluor-4000 multi-well fluorescence plate reader (Perceptive Biosystems) using excitation wavelength 360 nm and emission wavelength 460 nm, or using other suitable spectrofluorometer. In preparation for the assay, test compounds are initially prepared at 10 mM in dimethylsulfoxide. All subsequent dilutions and assay additions are made in 10 mM potassium phosphate buffer, pH 7.0.

X-ray crystallography of the inhibitor-aP2 complex can be performed by one skilled in the art using contemporary biophysical methodologies and commercial instrumentation. Such crystallographic data can be used to conclusively determine if a compound used in the present invention has embodied the structural requirement necessary for inhibition of aP2. An example of such an X-ray crystallographic determination is presented below:

Crystals of aP2 complexed with the inhibitors were typically grown by the hanging drop method. aP2, at 8.3 mg/ml, was pre-equilibrated with 1-5 mM of the inhibitor in 0.1 M Tris-HCl pH 8.0, 1% w/v DMSO for four hours. 2 μ l drops containing equilibrated protein and reservoir solution at a 1:1 ratio were suspended on plastic cover slips and equilibrated against a 1 ml reservoir containing 2.6-3.0 M ammonium sulfate in 0.1 M Tris-HCl pH 8.0. Crystals typically appeared in 2-3 days and reached maximum

size within 2 weeks. Data was typically collected on a single flash-frozen crystal (Oxford Cryosystems) using a Rigaku rotating anode and an R-axis II image plate detector of a Bruker multiwire area detector. Diffraction from aP2 crystals was excellent. Diffraction was consistently observed to better than 2.0 Å resolution often to beyond 1.5 Å resolution. Data was processed either with DENZO/SCALEPACK (R-axis II data), or Xengen (Bruker data). XPLOR was used for structure refinement and model building was done using the molecular modeling package CHAIN. After a single round of refinement, examination of the $F_o - F_c$ map typically allowed facile building of the inhibitor into aP2 binding cavity. Iterative fitting and refinement were continued until improvement was no longer seen in the electron density map or R-free.

Referring to the accompanying Figure which is a computer generated image of a partial X-ray structure of compound XVIA bound to human aP2, the ball and stick figure in light gray is compound XVIA. The Arg106, Arg126, and Tyr128 residues are depicted as ball and stick figures in dark gray. The dark spheres represent a space filling view of the discrete binding pocket comprised of the residues Phe16, Tyr19, Met20, Val23, Val25, Ala33, Phe57, Thr74, Ala75, Asp76, Arg78. The 4-chlorophenyl substituent of compound XVIA is shown bound within this discrete pocket and the hydroxyl group is bound to the Arg-Tyr-Arg residues.

What is claimed is:

1. A method for treating atherosclerosis which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of an aP2 inhibitor.

2. The method as defined in Claim 1 wherein the aP2 inhibitor binds to the aP2 protein and inhibits its function and/or its ability to bind free fatty acids.

3. The method as defined in Claim 1 wherein the aP2 inhibitor contains a hydrogen bond donator or acceptor group and interacts directly or through an intervening water molecule either by ionic or hydrogen bonding interactions, with one, two, or three of the three amino acid residues, designated as Arg 106, Arg 126 and Tyr 128 in human aP2 within the aP2 protein.

4. The method as defined in Claim 3 wherein the hydrogen bond donator or acceptor group is acid in nature.

5. The method as defined in Claim 3 where said aP2 inhibitor contains an additional substituent which binds to (in) and/or interacts with a discrete pocket within the aP2 protein defined roughly by the amino acid residues Phe 16, Tyr 19, Met 20, Val 23, Val 25, Ala 33, Phe 57, Thr 74, Ala 75, Asp 76, Arg 78 in human aP2.

6. The method as defined in Claim 5 wherein said additional substituent in said aP2 inhibitor is hydrophobic in nature.

7. The method as defined in Claim 5 in which the through space distance from the hydrogen bond donor/acceptor group and the additional substituent group in said aP2 inhibitor is within the distance of about 7 to about 15 Angstroms.

8. The method as defined in Claim 1 wherein Type II diabetes is treated.

9. The method as defined in Claim 1 wherein the aP2 inhibitor is employed in the form of a pharmaceutically acceptable salt thereof or a prodrug ester thereof.

10. The method as defined in Claim 1 wherein the aP2 inhibitor includes an oxazole or analogous ring, a pyrimidine derivative or a pyridazinone derivative.


11. The method as defined in Claim 10 wherein the aP2 inhibitor is a substituted benzoyl or biphenyl-2-oxazole-alkanoic acid derivative, an oxazole derivative, a 2-thio-4,5-diphenyloxazole S-derivative, a phenyl-heterocyclic oxazole derivative, a diaryloxazole derivative, a 4,5-diphenyloxazole derivative, an oxazole carboxylic acid derivative, a phenyloxazolyloxazole derivative, or a 2-(4,5-diaryl)-2-oxazolyl substituted phenoxyalkanoic acid derivative.

12. The method as defined in Claim 10 wherein the aP2 inhibitor is a 2-benzyloxypyrimidine derivative, a dihydro(alkylthio)(naphthylmethyl)oxypyrimidine derivative, a thiouracil derivative, or an α -substituted pyrimidine-thioalkyl or alkyl ether derivative.

13. The method as defined in Claim 10 wherein the aP2 inhibitor is a pyridazinone acetic acid derivative.


14. The method as defined in Claim 10 wherein the aP2 inhibitor is

(I) a substituted benzoylbenzene or biphenyl alkanoic acid derivative having the structure:




wherein

A is a group having the formula




wherein

X is -N- or




Z is



5

 R^1 is hydrogen, lower alkyl or phenyl; R^2 is hydrogen or lower alkyl; or

R^1 and R^2 taken together form a benzene ring, with the proviso that when X is -N-, Z is other than




10

 R^3 is hydrogen or lower alkyl;

n is 1-2;

B is




15 wherein

Y is OR^5 or N(OH)R^8 ;

R^4 and R^5 are each, independently, hydrogen or lower alkyl;

 R^6 is hydrogen, halo or nitro;

20


 R^7 is R^8 is lower alkyl;

m is 0-3;

25 or a pharmacologically acceptable salts thereof;

(II) oxazole derivatives which have the structure

II



in which;


R and R' are identical or different and represent a
 5 hydrogen atom or an alkyl radical containing 1 or 2 carbon
 atoms,

R₁ and R₂ are identical or different and represent
 hydrogen or halogen atoms or alkyloxy radicals in which the
 alkyl portion contains 1 to 4 carbon atoms in a straight or
 10 branched chain, and

n equals 3 to 6, as well to their salts;

(III) 2-thiol-4,5-diphenyloxazole S-derivatives
 which have the structure


III



15 wherein m is 0, 1 or 2, n is 1 and R represents hydroxy,
 alkoxy or amino, and pharmaceutically acceptable addition
 salts thereof;

(IV) azole derivatives of the structure




IV



20 wherein R₁ is carboxyl, esterified carboxyl or other
 functionally modified carboxyl group; R₂ and R₃ each are
 aryl of up to 10 carbon atoms; A is C_nH_{2n} in which n is an
 25 integer from 1 to 10, inclusive; and Z is O or S, and
 physiologically acceptable salts thereof;

(V) phenyl-heterocyclic oxazole derivatives which have the structure

V



5

R is CH_2R^2 ;

R^1 is Ph or Th;

R^2 is



CO_2R^3 ; and


10

R^3 is H, or C_1 - C_4 lower alkyl;

or pharmaceutically acceptable salt thereof;

(VI) diaryloxazole derivatives having the structure

VI





15 wherein R^1 is carboxy or protected carboxy,

R^2 is aryl,

R^3 is aryl,

A^1 is lower alkylene,


A² is bond or lower alkylene and
-Q- is



(in which is cyclo (lower)alkane or
cycle(lower)alkene,
each of which may have suitable substituent(s));
(VII) 4,5-diphenyloxazole derivatives having the

structure

VIIA



10

wherein

R is H or C₁-C₅ lower alkyl,

X is N or CH,


Y is H or CO₂R¹, or COR², provided that when X is CH,

15 Y is not H,

R¹ is C₁-C₅ lower alkyl, or phenylmethyl, and

R² is C₁-C₅ alkyl;

VIIIB



20 wherein

R is H or C₁-C₅ lower alkyl,

X is $(CH_2)_n$ or para or meta substituted phenyl
wherein the substituent is OR^2 ,


R^2 is C_1 - C_5 alkyl, and

n is an integer of 4 to 8,

5 and pharmaceutically acceptable salts thereof;

(VIII) oxazole carboxylic acid derivatives having
the structure

VIII



10

wherein

Y and Z are independently hydrogen or together form
a bond;

X is CN, CO_2R^1 or $CONR^2R^3$;


15 R and R^1 are independently or together H, Na, or
 C_1 - C_5 lower alkyl;

R^2 and R^3 are independently or together H, or C_1 - C_5
lower alkyl;

or alkali metal salt thereof;





20 (IX) phenyloxazolyloxazole derivatives having the
structure

IX




wherein

X is



25


Y is CH₃, Ph, or OH, provided that when Y is OH, the compound exists in the keto-enol tautomerism form



- 5 R¹ is Ph or Th;
 R² is CH₂R³;
 R³ is CO₂R⁴;
 R⁴ is H or C₁-C₅ lower alkyl;
 R⁵ is H or CH₃; R⁶ is OHCHN or H₂N; and
 R⁷ is H or OH;


- 10 or pharmaceutically acceptable salt thereof;
 (X) 2-(4,5-diaryl)-2-oxazolyl substituted
 phenoxyalkanoic acids and esters having the structure

XA




15

XB




(wherein n is 7-9 and R is hydrogen or lower alkyl; or when R is hydrogen, the alkali metal salt thereof),

XC



20

XD



wherein

R₁ is phenyl or thienyl;

R_2 is hydrogen, lower alkyl or together with CO_2 is tetrazol-1-yl;


X is a divalent connecting group selected from the group consisting of CH_2CH_2 , $CH=CH$, and CH_2O ;

5 Y is a divalent connecting group attached to the 3- or 4-phenyl position selected from the group consisting of OCH_2 , CH_2CH_2 and $CH=CH$,

or when R_2 is hydrogen, an alkali metal salt thereof;

(XI) substituted 4,5-diaryl heterocycles having the
10 formula

XI



in which

each group Ar is the same or different and is
15 optionally substituted phenyl or optionally substituted heteroaryl;

X is nitrogen or CR^1 ;

Y is nitrogen, $N(CH_2)_nA$ or $C(CH_2)_nA$;

Z is nitrogen, oxygen or $N(CH_2)_nA$, and the dotted
20 line indicates the optional presence of a double bond so as to form a fully unsaturated heterocyclic ring;

R^1 is hydrogen, C_{1-4} alkyl, optionally substituted phenyl or optionally substituted heteroaryl;


n is 4 to 12; and

25 A is CO_2H or a group hydrolysable to CO_2H , 5-tetrazolyl, SO_3H , $P(O)(OR)_2$, $P(O)(OH)_2$, or $P(O)(R)(OR)$ in which R is hydrogen or C_{1-4} alkyl, or a pharmaceutically acceptable salt thereof;

(XII) compounds which have the structure

30

XII



Where X is O or S;


R₁ is H, phenyl or phenyl substituted with F, Cl or Br or alkoxy,

R₂ is H, alkyl, phenyl or phenyl substituted with F, Cl or Br or alkoxy, and

5 R₃ is H or alkyl;

(XIII) 2-benzyloxypyrimidine derivatives having the following structure

XIII



10 wherein

R¹ and R² are each independently H, a halogen, hydroxyl, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₅ alkenyl, C₃-C₅ alkynyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₃-C₅ alkenyloxy, C₃-C₅ alkynyloxy, C₁-C₄ alkylthio, or phenyl, with the


15 proviso that at least one of R¹ and R² must be hydroxyl; n is an integer of 0 to 5; and

each X which may be identical or different if n is greater than 1, is a halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₇-C₉ aralkyloxy, phenyl, hydroxymethyl, hydroxycarbonyl, C₁-C₄ alkoxy carbonyl, or

20 nitro;

(XIV) dihydro(alkylthio)-(naphthylmethyl)-oxypyrimidines which have the structures


XIVA




3a R=sec-butyl
3b R=cyclopentyl
3c R=cyclohexyl

25

XIVB




XIVC




5

XIVD




XIVE



R^1 = sec-butyl, cyclopentyl, cyclohexyl;
 10 R^2 = H, CH_3 , including tautomers of the above;


(XVI) α -substituted pyrimidine-thioalkyl and
alkylether compounds which have the structure

XVI



5 where m is 0 or 1;

R^1 is selected from $-\text{CO}_2\text{R}_{53}$, $-\text{CONR}_{54}\text{R}_{55}$,



10 where s is 0 or 1, and R_{20} , R_{21} , R_{22} , R_{23} , R_{24} , and R_{25} are
the same or different and are selected from -H, C_1 - C_6
alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, C_3 - C_8
cycloalkyl, $-\text{CF}_3$, $-\text{NO}_2$, -halo, -OH, -CN, phenyl,
phenylthio, -styryl, $-\text{CO}_2(\text{R}_{31})$, $-\text{CON}(\text{R}_{31})(\text{R}_{32})$, $-\text{CO}(\text{R}_{31})$, -
15 $(\text{CH}_2)_n\text{N}(\text{R}_{31})(\text{R}_{32})$, $-\text{C}(\text{OH})(\text{R}_{31})(\text{R}_{33})$, $-(\text{CH}_2)_n\text{N}(\text{R}_{31})(\text{CO}(\text{R}_{33}))$,
 $(\text{CH}_2)_n\text{N}(\text{R}_{31})(\text{SO}_2(\text{R}_{33}))$, or where R_{20} and R_{21} , or R_{21} and R_{22} ,
or R_{22} and R_{23} are taken together to form a five or six-
membered saturated or unsaturated ring containing 0 or 1
oxygen, nitrogen or sulfur, where the unsaturated ring may
be optionally substituted with 1, 2 or 3, C_1 - C_6 alkyl, C_1 -
20 C_6 alkoxy, -OH, $-\text{CH}_2\text{OH}$, $-(\text{CH}_2)_n\text{N}(\text{R}_{31})(\text{R}_{32})$, $-\text{C}_3$ - C_8
cycloalkyl, $-\text{CF}_3$, -halo, $\text{CO}_2(\text{R}_{31})$, $-\text{CON}(\text{R}_{31})(\text{R}_{32})$, $-\text{CO}(\text{R}_{31})$,
 $-(\text{CH}_2)_n\text{N}(\text{R}_{31})(\text{CO}(\text{R}_{33}))$, $-(\text{CH}_2)_n\text{N}(\text{R}_{31})(\text{SO}_2(\text{R}_{33}))$, -CN, $-\text{CH}_2\text{CF}_3$
or $-\text{CH}(\text{CF}_3)_2$, or phenyl and the saturated ring may be
optionally substituted with 1, 2 or 3, C_1 - C_6 alkyl, C_1 - C_6
25 alkoxy, -OH, $-\text{CH}_2\text{OH}$ or $-(\text{CH}_2)_n\text{N}(\text{R}_{31})(\text{R}_{32})$ or one oxo ($=\text{O}$);
where n is 0-3 and R_{31} , R_{32} and R_{33} are the same or
different and are selected from

-H,

C_1 - C_6 alkyl,

phenyl optionally substituted with 1, 2 or 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH or -CN,

or where R₃₁ and R₃₂ taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -
5 piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, -4-(1-C₁-C₆alkyl)piperazinyl, or a member selected from

1-cyclohexenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-imidazolyl, 4-imidazolyl, 2-benzothiazolyl,
10 2-benzoxazolyl, 2-benzimidazolyl, 2-oxazolyl, 4-oxazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 5-methyl-3-isoxazolyl, 5-phenyl-3-isoxazolyl, 4-thiazolyl, 3-methyl-2-pyrazinyl, 5-methyl-2-pyrazinyl, 6-methyl-2-pyrazinyl, 5-chloro-2-thienyl, 3-furyl, benzofuran-2-yl, benzothien-2-
15 yl, 2H-1-benzopyran-3-yl, 2,3-dihydrobenzopyran-5-yl, 1-methylimidazol-2-yl, quinoxalin-2-yl, piperon-5-yl, 4,7-dichlorobenzoxazol-2-yl, 4,6-dimethylpyrimidin-2-yl, 4-methylpyrimidin-2-yl, 2,4-dimethylpyrimidin-6-yl, 2-methylpyrimidin-4-yl, 4-methylpyrimidin-6-yl, 6-
20 chloropiperon-5-yl, 5-chloroimidazol[1,2-a]pyridin-2-yl, 1-H-inden-3-yl, 1-H-2-methyl-inden-2-yl, 3,4-dihydronaphth-1-yl, S-4-isopropenylcyclohexen-1-yl or 4-dihydronaphth-2-yl;

where R₅₃ is selected from -H, C₁-C₆alkyl, C₃-C₆cycloalkyl, phenyl (optionally substituted with 1, 2, or
25 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH, -CN), or a five or six-membered unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with -H, C₁-C₆ alkyl, C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂);

30 where R₅₄ and R₅₅ being the same or different are selected from -H, C₁-C₆ alkyl, allyl, or phenyl (optionally substituted with 1, 2 or 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy or -CF₃), or taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, -4-(1-C₁-
35 C₆alkyl)piperazinyl;

R₄₁ and R₄₂, being the same or different, are selected from -H and C₁-C₄ alkyl;

R₁₂ is selected from -H, C₁-C₆ alkyl, -C₃-C₆ cycloalkyl, -CN, -C(O)NH₂, -C(O)N(C₁-C₆alkyl)(C₁-C₆alkyl), -
5 CO₂H, -CO₂(C₁-C₆alkyl), -CH₂OH, -CH₂NH₂ or -CF₃;

R₁₃ is selected from -H, C₁-C₆ alkyl or -CF₃;

Y is selected from -S-, -S(O)-, -S(O)₂, or -O-;

R₄ is -OH;

R₅ is selected -H, -C₂H₄OH, -C₂H₄-O-TBDMS, halo, -C₃-
10 C₆ cycloalkyl, C₁-C₃ alkoxy, -CH₂CH₂Cl or C₁-C₄ alkyl, with the proviso that R₅ is not isobutyl;

or, when R₆ is hydroxyl, R₄ and R₅ are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group
15 consisting of 7H-pyrrolo[2,3-d]pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidine, furo[2,3-d]pyrimidine, 5,6-dihydro-furo[2,3-d]pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro-thieno[2,3-d]pyrimidine, 1H-pyrazolo[3,4-d]pyrimidine, 1H-purine, pyrimido[4,5-d]pyrimidine,
20 pteridine, pyrido[2,3-d]pyrimidine, or quinazoline, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C₁-C₆ alkyl C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂), -C₃-C₈ cycloalkyl, -CF₃, -halo, -CO₂(R₃₁), -CON(R₃₁)(R₃₂), -CO(R₃₁), -(CH₂)_nN(R₃₁)(CO(R₃₃)), -
25 (CH₂)_nN(R₃₁)(SO₂(R₃₃)), and the saturated ring may be optionally substituted with 1, 2 or 3, -C₁-C₆ alkyl, C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂) or one oxo (=O); and

R₆ is selected from -H, -OH, halo, -CN, -CF₃, -
30 CO₂(R₆₁), -C(O)R₆₁ or -C(O)N(R₆₁)(R₆₂) where R₆₁ and R₆₂ are the same or different and are selected from

-H,

C₁-C₆ alkyl,


phenyl optionally substituted with 1, 2 or 3 -halo,
35 C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH, -CN,

or where R₆₁ and R₆₂ taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -


piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, or -4-(C₁-C₆ alkyl)piperazinyl;

pharmaceutically acceptable salts, hydrates, N-oxides and solvates thereof;

5 (XVII) compounds which have the structure



XVIIA



XVIIIB

where R₁ and R₂ are H, alkyl, aryl or arylalkyl, where the alkyl can include as substituents halogen, CF₃, CH₃O, CH₃S, NO₂, or R₁ and R₂ with the carbons to which they are attached can form methylenedioxy, or





R₁ and R₂ can form a C₃-C₇ non-aromatic ring, or a heterocycle which can be pyridine, pyrazine, pyrimidine, pyridazine, indol, or pyrazole, or an oxygen containing heterocycle which can be pyran or furan, or a sulfur containing heterocycle which can be thiopyran, or thiophene; the heterocycles being optionally substituted with halogen or alkyl,

R₃ and R₄ are H, alkyl, halogen, CF₃, CH₃O, CH₃S or NO₂ or R₃ and R₄ with the carbons to which they are attached can form a methylenedioxy group,

R₅ is H, and

Z is a heterocycle which can be pyridine, thiazole, benzothiazole, benzimidazole or quinoline, which Z group can optionally be substituted with halogen or alkyl.

15. The method as defined in Claim 1 wherein the aP2 inhibitor has the structure



16. A pharmaceutical combination comprising an aP2 inhibitor and another type antiatherosclerotic agent.


17. The combination as defined in Claim 16 wherein the other antiatherosclerotic agent is an MTP inhibitor, an
5 HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, other cholesterol lowering agent, a lipoxygenase inhibitor, an ACAT inhibitor or a PPAR α/γ dual agonist.

18. The combination as defined in Claim 16 wherein
10 the antiatherosclerotic agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin or fluvastatin.

19. The combination as defined in Claim 16 wherein the aP2 inhibitor is present in a weight ratio to the antiatherosclerotic agent within the range from about 0.01
15 to about 100:1.

20. A method for treating atherosclerosis which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim 16.

20



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21069

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/50, 31/505, 31/42

US CL :514/247, 274, 374, 824

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/247, 274, 374, 824

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE: ap2 inhibitor, albp, adipocyte lipid binding protein with atherosclero?, lipid?, cholesterol?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE ON STN, ASSESSION NO. 126:17417 HOTMISLIGIL, G.S. et al. 'Uncoupling of Obesity From Insulin Resistance Through a Targeted Mutation in aP2, The Adipocyte Fatty Acid Binding Protein.' Science (Washington, D.C.) 1996, 274(5291), 1377-1379.	1-20
A	US 5,218,124 A (FAILLI et al) 08 June 1993, see entire document.	1-20

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation for other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 JANUARY 2000

Date of mailing of the international search report

10 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks

Authorized officer